Campbell & CO Investment Adviser LLC Incyte Corp Transaction History

Campbell & CO Investment Adviser LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$52.16 - $64.19 $246,925 - $303,875	4,734 New	4,734 $297,000
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $940,519 - $1.17 Million	15,431 New	15,431 $960,000
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $250,715 - $313,898	3,732 New	3,732 $299,000
Q1 2020 Apr 29, 2020	SELL	$63.18 - $85.97 $535,260 - $728,337	-8,472 Closed	0 $0
Q4 2019 Jan 23, 2020	BUY	$73.04 - $95.72 $618,794 - $810,939	8,472 New	8,472 $740,000
Q3 2018 Nov 08, 2018	SELL	$61.75 - $74.23 $291,213 - $350,068	-4,716 Closed	0 $0
Q2 2018 Jul 13, 2018	BUY	$60.85 - $83.98 $286,968 - $396,049	4,716 New	4,716 $316,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.